(Q48454295)

English

Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine.

scientific article published in January 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

1 reference

based on heuristic

inferred from title

Paul R. Sanberg

5

object named as

Paul R Sanberg

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

author name string

R Douglas Shytle

1

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

Archie A Silver

2

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

Kathy H Sheehan

3

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

David V Sheehan

4

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

publication date

1 January 2002

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

Depression and Anxiety

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

16

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

3

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

89-92

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol

1 reference

https://api.crossref.org/works/10.1002%2FDA.10035

21 January 2018

Cigarette smoking and major depression

1 reference

https://api.crossref.org/works/10.1002%2FDA.10035

21 January 2018

Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function

1 reference

https://api.crossref.org/works/10.1002%2FDA.10035

21 January 2018

Nicotinic acetylcholine receptor antagonistic activity of monoamine uptake blockers in rat hippocampal slices

1 reference

https://api.crossref.org/works/10.1002%2FDA.10035

21 January 2018

A nicotine antagonist, mecamylamine, reduces cue-induced cocaine craving in cocaine-dependent subjects

1 reference

https://api.crossref.org/works/10.1002%2FDA.10035

21 January 2018

Mecamylamine in Tourette's syndrome: a two-year retrospective case study.

1 reference

https://api.crossref.org/works/10.1002%2FDA.10035

21 January 2018

Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette's disorder

1 reference

https://api.crossref.org/works/10.1002%2FDA.10035

21 January 2018

Antidepressant effects of nicotine in an animal model of depression.

1 reference

https://api.crossref.org/works/10.1002%2FDA.10035

21 January 2018

Mecamylamine: new therapeutic uses and toxicity/risk profile

1 reference

https://api.crossref.org/works/10.1002%2FDA.10035

21 January 2018

Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy.

1 reference

https://api.crossref.org/works/10.1002%2FDA.10035

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of Tourette's syndrome with mecamylamine

1 reference

https://api.crossref.org/works/10.1002%2FDA.10035

7 January 2021

based on heuristic

inferred from DOI database lookup

Comorbid bipolar disorder in Tourette's syndrome responds to the nicotinic receptor antagonist mecamylamine (Inversine)

1 reference

https://api.crossref.org/works/10.1002%2FDA.10035

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DA.10035

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 February 2018

http://europepmc.org/abstract/MED/12415531

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48454295&oldid=1533748304"